164 related articles for article (PubMed ID: 9395033)
1. Long-term survival of patients with acute myeloid leukemia: a third follow-up of the Fourth International Workshop on Chromosomes in Leukemia.
Bloomfield CD; Shuma C; Regal L; Philip PP; Hossfeld DK; Hagemeijer AM; Garson OM; Peterson BA; Sakurai M; Alimena G; Berger R; Rowley JD; Ruutu T; Mitelman F; Dewald GW; Swansbury J
Cancer; 1997 Dec; 80(11 Suppl):2191-8. PubMed ID: 9395033
[TBL] [Abstract][Full Text] [Related]
2. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
Bloomfield CD; Lawrence D; Byrd JC; Carroll A; Pettenati MJ; Tantravahi R; Patil SR; Davey FR; Berg DT; Schiffer CA; Arthur DC; Mayer RJ
Cancer Res; 1998 Sep; 58(18):4173-9. PubMed ID: 9751631
[TBL] [Abstract][Full Text] [Related]
3. Correlation between CD34 expression and chromosomal abnormalities but not clinical outcome in acute myeloid leukemia.
Fruchart C; Lenormand B; Bastard C; Boulet D; Lesesve JF; Callat MP; Stamatoullas A; Monconduit M; Tilly H
Am J Hematol; 1996 Nov; 53(3):175-80. PubMed ID: 8895688
[TBL] [Abstract][Full Text] [Related]
4. Intensive treatment of patients age 60 years and older with de novo acute myeloid leukemia: analysis of prognostic factors.
Stasi R; Venditti A; Del Poeta G; Aronica G; Dentamaro T; Cecconi M; Stipa E; Scimò MT; Masi M; Amadori S
Cancer; 1996 Jun; 77(12):2476-88. PubMed ID: 8640696
[TBL] [Abstract][Full Text] [Related]
5. Remission induction therapy of untreated acute myeloid leukemia using a non-cytarabine-containing regimen of idarubicin, etoposide, and carboplatin.
Bow EJ; Gallant G; Williams GJ; Woloschuk D; Shore TB; Rubinger M; Schacter BA
Cancer; 1998 Oct; 83(7):1344-54. PubMed ID: 9762935
[TBL] [Abstract][Full Text] [Related]
6. A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia.
Bassan R; Lerede T; Buelli M; Borleri G; Bellavita P; Rambaldi A; Barbui T
Haematologica; 1998 May; 83(5):422-7. PubMed ID: 9658726
[TBL] [Abstract][Full Text] [Related]
7. Outcome assessment of age group-specific (+/- 50 years) post-remission consolidation with high-dose cytarabine or bone marrow autograft for adult acute myelogenous leukemia.
Bassan R; Raimondi R; Lerede T; D'emilio A; Buelli M; Borleri G; Personeni A; Bellavita P; Rodeghiero F; Barbui T
Haematologica; 1998 Jul; 83(7):627-35. PubMed ID: 9718868
[TBL] [Abstract][Full Text] [Related]
8. Multidrug resistance-associated protein in acute myeloid leukemia: No impact on treatment outcome.
Filipits M; Suchomel RW; Zöchbauer S; Brunner R; Lechner K; Pirker R
Clin Cancer Res; 1997 Aug; 3(8):1419-25. PubMed ID: 9815827
[TBL] [Abstract][Full Text] [Related]
9. Patients with isolated trisomy 8 in acute myeloid leukemia are not cured with cytarabine-based chemotherapy: results from Cancer and Leukemia Group B 8461.
Byrd JC; Lawrence D; Arthur DC; Pettenati MJ; Tantravahi R; Qumsiyeh M; Stamberg J; Davey FR; Schiffer CA; Bloomfield CD
Clin Cancer Res; 1998 May; 4(5):1235-41. PubMed ID: 9607582
[TBL] [Abstract][Full Text] [Related]
10. P-glycoprotein expression and prognostic value in acute myeloid leukemia.
Senent L; Jarque I; Martín G; Sempere A; González-García Y; Gomis F; Pérez-Sirvent M; De La Rubia J; Sanz MA
Haematologica; 1998 Sep; 83(9):783-7. PubMed ID: 9825574
[TBL] [Abstract][Full Text] [Related]
11. Intensive short-term chemotherapy for patients with acute myelogenous leukemia: long-term follow-up.
Oblon DJ; Weiner RS; Kramer BS; Ross W; Noyes WD; Boyett J; Kitchens CS
Cancer Treat Rep; 1985 Dec; 69(12):1425-7. PubMed ID: 2416439
[TBL] [Abstract][Full Text] [Related]
12. Long-term survival in acute leukemia. Twenty-two adult patients surviving for over five years.
Evensen SA; Stavem P
Acta Med Scand; 1986; 219(1):79-83. PubMed ID: 3456695
[TBL] [Abstract][Full Text] [Related]
13. De novo acute myeloid leukaemia in patients over 55-years-old: a population-based study of incidence, treatment and outcome. Northern Region Haematology Group.
Taylor PR; Reid MM; Stark AN; Bown N; Hamilton PJ; Proctor SJ
Leukemia; 1995 Feb; 9(2):231-7. PubMed ID: 7532766
[TBL] [Abstract][Full Text] [Related]
14. [Diagnosis and treatment strategy for de novo AML with trilineage myelodysplasia].
Kuriyama K
Rinsho Ketsueki; 1994 Mar; 35(3):267-71. PubMed ID: 8158847
[TBL] [Abstract][Full Text] [Related]
15. Certain HLA antigens are associated with specific morphologic and cytogenetic subsets of acute myeloid leukemia.
Joventino LP; Stock W; Lane NJ; Daly KM; Mick R; Le Beau MM; Larson RA
Leukemia; 1995 Mar; 9(3):433-9. PubMed ID: 7885042
[TBL] [Abstract][Full Text] [Related]
16. Cytogenetic and clinical correlates in AML patients with abnormalities of chromosome 16.
Marlton P; Keating M; Kantarjian H; Pierce S; O'Brien S; Freireich EJ; Estey E
Leukemia; 1995 Jun; 9(6):965-71. PubMed ID: 7596186
[TBL] [Abstract][Full Text] [Related]
17. Circulating immune complexes correlate with remission duration in acute myeloid leukemia.
Larson RA; Lukin CL; Daly KM; Mick R; Gore S; Le Beau MM
Leukemia; 1991 Feb; 5(2):131-7. PubMed ID: 2020195
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of cytogenetics in acute myeloid leukemia.
Mrózek K; Heinonen K; de la Chapelle A; Bloomfield CD
Semin Oncol; 1997 Feb; 24(1):17-31. PubMed ID: 9045301
[TBL] [Abstract][Full Text] [Related]
19. Dose-reduced induction therapy for acute leukaemias decreases both the complete remission (CR) rate and the probability of leukaemia-free survival (LFS).
Krahl R; Helbig W; Kubel M
Folia Haematol Int Mag Klin Morphol Blutforsch; 1990; 117(6):783-6. PubMed ID: 1713882
[TBL] [Abstract][Full Text] [Related]
20. [Long term follow-up of three cases of acute myeloid leukemia associated with inv(16)(p13q22)].
Miura I; Cyubachi A; Hashimoto K; Nishinari T; Nimura T; Miura AB
Rinsho Ketsueki; 1993 Aug; 34(8):942-5. PubMed ID: 8411649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
